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 Introduction 
 Diarrhea is a clinical symptom reflecting abnormali-
ties in the gastrointestinal tract of a variety of different 
diseases. Diarrhea developing in immunocompromised 
individuals differs from diarrhea developing in immuno-
competent individuals with respect to the spectrum of 
underlying causes, pathophysiological mechanisms, clin-
ical presentation and histopathological findings. Integrity 
of the intestinal mucosa is one of the many factors re-
quired for a normal bowel function. The intestinal epithe-
lial layer at the mucosal surface has a barrier function 
which is crucial for mucosal integrity. The intestinal epi-
thelium is a dynamic compartment and is subject to per-
manent turnover and regeneration in case of injury. In-
testinal epithelial cells (EC) have a high turnover rate and 
are estimated to be replaced every 3–5 days. Besides phys-
iological shedding of intestinal EC into the bowel lumen, 
intestinal EC may be lost as the result of damage to the 
epithelium. A morphological correlate of such damage is 
the occurrence of apoptosis in intestinal EC.
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 Abstract 
 Background/Aims: Diarrhea developing in patients under 
immunosuppression has a variety of underlying causes. A 
broad spectrum of histological findings can be found in in-
testinal biopsies taken for the diagnostic workup of diarrhea 
including a pathologically increased proportion of epithelial 
cell apoptosis in the colon, for which the descriptive term 
‘apoptotic colonopathy’ was coined. In recent years, the im-
munosuppressive drug mycophenolate (mycophenolic acid, 
MPA) has been identified as a prototypical cause of apop-
totic colonopathy, but other conditions may show similar or 
overlapping histological pictures.  Methods: Cases of likely
or possible MPA colonopathy (n = 18) were retrospectively 
identified from the archive files. Clinical information on pa-
tient history, clinical presentation and endoscopic findings 
were recorded. All cases were routinely processed, i.e. stained 
by hematoxylin and eosin (HE) stain, optionally supplement-
ed by special histochemical and immune stains.  Results and 
Conclusion: Histopathological hallmarks of MPA treatment-
related changes in the colon mucosa are reviewed with re-
spect to the major histopathological differential diagnoses 
including normal and near-normal findings, infectious dis-
eases, graft-versus-host disease and inflammatory bowel dis-
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 Materials and Methods 
 For this study, cases of likely or possible mycophenolate (my-
cophenolic acid, MPA) colonopathy were retrospectively iden-
tified from the files of the Institute of Surgical Pathology, Uni-
versity Hospital Zurich, for the period 2009–2012. Clinical infor-
mation on patient history, clinical presentation and endoscopic 
findings were recorded, when available, from clinical information. 
All cases were routinely processed, i.e. stained by hematoxylin and 
eosin (HE) stain, optionally supplemented by special histochemi-
cal and immune stains for suspected infectious agents. Overall, we 
identified 18 cases of likely or possible MPA colonopathy in 16 
different patients (rebiopsies in 2 cases; see  table 1 ). The study was 
in line with the local ethical regulations (Reglement für den Zugriff 
auf Patientendaten zu Forschungszwecken; University Hospital 
Zurich).
 Apoptosis in Normal Colonic Mucosa and Bowel 
Preparation Effects 
 As it takes more than one swallow to make a summer, 
it takes more than one colonic apoptosis to make a co-
lonic pathology. A single apoptotic intestinal EC in an 
otherwise unremarkable colonic mucosa is not abnormal 
per se. In early studies performed to quantify how many 
apoptoses can be found in a nondiseased colonic mucosa, 
a threshold of 5 apoptotic bodies per 100 crypts found in 
an HE-stained slide has been determined  [1] . When eval-
uating colonic biopsies, one has to be aware of histologi-
cal changes resulting from the bowel preparation proce-
dure; this includes scattered apoptosis of colonic EC  [2] . 
For practical purposes, the finding of more than an oc-
casional apoptotic colonic EC should be regarded as ab-
normal and prompt a search for an underlying condition. 
The histological finding of a pathologically increased 
number of apoptoses in the colon mucosa is coined with 
the generic term apoptotic colonopathy.
 MPA-Induced Colonopathy 
 In recent years, we increasingly observed colonic biop-
sies taken for the clinical workup of diarrhea that revealed 
(among others) the finding of apoptotic colonopathy 
which was ultimately related to the use of the immuno-
suppressive drug MPA. This observation in our practice 
was paralleled by a growing body of literature on MPA-
Table 1.  Histological findings in colon biopsies of patients with (suspected) MPA colonopathy
No. Age Sex Med hx Clinical presentation Biopsy information Histological findings Additional findings Cau-
salitya
1 60 M K-TPL watery diarrhea colon ACE, CDC, CAD, inflammation erosions ++
2 70 M K-TPL diarrhea colon ACE, CAD, inflammation ++
3 75 M K-TPL diarrhea colon frame ACE, CAD, inflammation ++
4 58 M K-TPL diarrhea colon frame ACE IEL +
5 40 M K-TPL diarrhea colon frame ACE, CDC, CAD, inflammation ++
6 45 F K/P-TPL diarrhea colon frame ACE, CAD kayexalate +
7 48 M K-TPL diarrhea colon steps ACE, CDC, CAD, inflammation, EOS ++
8 26 F K-TPL diarrhea with blood colon right and left ACE, CAD, inflammation mucinous granulomas +
9 43 F L-TPL weight loss colon, 45 cm ACE, CAD, inflammation +
10 53 M K-TPL diarrhea colon ACE, CDC, CAD, inflammation, EOS ++
11 65 M K-TPL diarrhea colon, rectum ACE, CDC, CAD, inflammation, EOS muciphages +
12 54 F K-TPL diarrhea colon ACE, CAD, inflammation CMV reactivation ++
13 38 F K-TPL abdominal pain colon ACE, CAD, inflammation +
14 64 M K-TPL diarrhea colon frame ACE, CAD, inflammation, EOS ++
15 54 F K-TPL diarrhea, weight loss colon ACE, CAD, inflammation same patient as No. 12 +
16 11 F SLE diarrhea cecum, rectum ACE, CDC, CAD, inflammation, EOS thrombotic microangiopathy +
17 38 F K-TPL abdominal pain, weight loss colon ACE, CDC, CAD, inflammation same patient as No. 13 +
18 53 F K-TPL diarrhea colon ACE, CDC, CAD, inflammation, erosions CMV infection, tapeworm +
 ACE = Apoptosis of crypt epithelium; CAD = crypt architectural disarray; CDC = cystically dilated crypts; EOS = eosinophils; IEL = intraepithelial lympho-
cytosis; K/P-TPL = combined kidney and pancreas transplantation; K-TPL = kidney transplantation; SLE = systemic lupus erythematosus; Med hx = medical 
history.
a Changes due to MPA are possible (+) or likely (++), when regarding the symptoms and histological findings.
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related histopathological findings  [3–6] . MPA is an in-
hibitor of inosine-5 ′ -monophosphate dehydrogenase 
and blocks the de novo purine synthesis required for 
DNA synthesis and cell division. MPA and its prodrug 
mycophenolate mofetil (MMF) have several immuno-
suppressant actions and prevent allograft rejection by 
several mechanisms: proliferation of T and B lympho-
cytes is inhibited and cell-mediated immune responses 
and antibody formation are suppressed, dendritic cell 
maturation impaired and anti-inflammatory activity fur-
ther impaired by the inhibition of interleukin (IL-1) ex-
pression together with the enhanced expression of the 
IL-1 receptor antagonist  [7] . MPA is frequently used to 
prevent rejection in (solid) organ transplantations, and is 
available either as the prodrug MMF (CellCept ® , Roche 
Pharma AG, Reinach, Switzerland) or the salt mycophe-
nolate sodium (Myfortic ® , Novartis Pharma AG, Stein, 
Switzerland), differing mostly with respect to a more gas-
tric or enteric absorption, respectively  [8] .
 Among other adverse effects, MPA may also cause 
damage to the gastrointestinal tract  [9] . Typical clinical 
presentations of MPA-related gastrointestinal toxicity in-
clude afebrile, watery diarrhea with mostly unremarkable 
or mild endoscopy findings. The entire gastrointestinal 
tract including the upper part can be affected by MPA 
toxicity  [3] , and macroscopic features may include ulcers 
and erosions throughout the entire gut. The epithelial or 
glandular compartment is the main target of MPA-relat-
ed toxicity. The predominant patterns of injury are an 
acute inflammatory pattern and/or an apoptotic pattern. 
Major histopathological findings comprise a picture re-
sembling self-limited colitis, an inflammatory bowel dis-
ease (IBD)-like picture and a graft-versus-host disease 
(GvHD)-like picture  [4, 6, 10] . Typical histological fea-
tures include a (mostly mild) crypt architectural disarray, 
colonic crypt atrophy and dropout which may result in an 
IBD-like pattern over time ( fig. 1 a, left), a paucity of in-
flammatory cells in the lamina propria (‘empty lamina 
propria appearance’), atrophy of the epithelial lining cells 
with typical dilated crypts containing an attenuated epi-
thelial lining and cellular debris in their lumen ( fig. 1 a, 
middle) and a notably increased number of crypt cell 
apoptoses ( fig. 1 a, right). As illustrated in  figure 1 a, the 
different histopathological key findings are best evaluated 
on low-power view (architecture, left), medium-power 
view (epithelial changes, middle) and high-power view 
(apoptosis, right), respectively. Whereas none of the 
above-mentioned findings is specific for MPA, the simul-
taneous observation of a mixed pattern of injury (archi-
tectural distortion, increased number of crypt cell apop-
tosis, epithelial changes with cystically dilated crypts) is 
characteristic for MPA toxicity  [6, 10–12] . Variably en-
countered additional findings are an increased number of 
eosinophils in the lamina propria and a (relatively) in-
creased number of neuroendocrine cells which seem to be 
less prone to undergo apoptosis.
 In contrast to the early years of MPA use, with an in-
creased awareness of MPA toxicity deriving from clinical 
sites, information on MPA treatment is nowadays fre-
quently given. The above-listed histopathological find-
ings – especially when a combination of the several pat-
terns is found – are so characteristic of MPA toxicity that 
this must be mentioned with the differential diagnoses in 
the pathology report, even when corresponding clinical 
information is lacking. In our experience, in such cases, 
communication with clinical partners regarding specific 
questions on MPA treatment can be helpful, in many in-
stances leading to the diagnosis.
 Differential Diagnoses 
 Unfortunately, even when the full spectrum of chang-
es listed is present, the above-listed histopathological 
findings are not restricted to cases of MPA toxicity. The 
most relevant differential diagnoses are listed in  table 2 
with respect to features useful for differential diagnostic 
considerations. As outlined, MPA toxicity can present 
with histological pictures resembling self-limited infec-
tious colitis, IBD and/or GvHD, respectively; these are 
thus obviously among the differential diagnoses. In daily 
practice, IBD is not a major differential diagnosis, as med-
ical history, clinical presentation and endoscopic findings 
of IBD patients are mostly different from patients with 
MPA colonopathy. Histopathologically, MPA colonopa-
thy and IBD may both have architectural disarray. How-
ever, IBD typically has an increased inflammatory infil-
trate in the lamina propria which is in contrast to the 
paucicellular (‘empty-appearing’) lamina propria in MPA 
colonopathy. Furthermore, IBD cases tend to have more 
features of chronicity, and metaplasia (mucinous or py-
loric-gland type) or granulomas can be found which are 
typically not seen in MPA colonopathy.
 In contrast, infectious colitis is a relevant differential 
diagnosis. Increased apoptosis of the crypt epithelium is 
a feature of infections caused by a variety of agents includ-
ing bacterial infections, especially the toxin-producing 
ones, and in particular viral infections caused by human 
cytomegalovirus (CMV) and adenovirus, but also proto-
zoal infections, especially  Cryptosporidium . Patients un-
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 Fig. 1.  a Histological hallmarks of MPA-related colonopathy. Left: 
IBD-like pattern with architectural disarray and empty appearing 
lamina propria. Middle: atrophic cystically dilated crypts (arrow) 
with luminal cellular debris. Right: multiple apoptosis of basal crypt 
epithelium cells (arrows). Magnification ×2.5, ×10 and ×10, respec-
tively.  b Colonic biopsy with GvHD revealing denudation of the 
surface epithelium, spare infiltrate of cells in the lamina propria, and 
multiple apoptosis of basal crypt epithelium cells (arrow). Magnifi-
cation ×5.  c Colonic biopsy of a case of AIDS-related colonopathy 
revealing also multiple apoptosis of basal crypt epithelium cells (ar-
rows). Magnification ×20.  d–g Colonic biopsy of a patient develop-
ing diarrhea while on treatment revealing multiple pathologies in-
cluding changes consistent with MPA-induced effects.  d Low-pow-
er view reveals mild architectural disarray: framed areas 1 and 2 have 
additional distinct findings. Magnification ×0.38.  e High-power 
view of area 1 in  d with a section of the dwarf tapeworm  (Hymenol-
epis nana) . Magnification ×10.  f ,  g High-power views of area 2 in
 d revealing active colitis with erosions, cystically dilated crypts and 
multiple EC with both nuclear and cytoplasmic inclusions indicat-
ing CMV infection. Magnification ×5 and ×10, respectively. 
 a 
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der immunosuppression, including that resulting from 
MPA treatment, are naturally at a higher risk for develop-
ing opportunistic infections. Consequently, even in cases 
with features suggesting MPA-related changes like in-
creased apoptosis of the crypt epithelium, the presence of 
concomitant infections must be determined, and a low 
threshold for further workup including more levels, spe-
cific and immune stains should be given.
 GvHD  [13] is probably the condition which shares the 
most histopathological features with MPA-related colo-
nopathy to a degree that a GvHD-like pattern is regarded 
as a characteristic feature of MPA-related colonopathy. 
Both conditions reveal a predominantly inflammatory 
injury pattern affecting the epithelial compartment. 
Apoptosis of the crypt epithelium is a hallmark of both as 
well as a paucity of lamina propria inflammatory cells. 
GvHD may progress to a condition with marked crypt 
distortion resembling IBD, similar to how MPA-related 
colonopathy does. Although on the one hand, MPA-re-
lated colonopathy often shows cystically dilated crypts 
( fig. 1 a, middle panel) which GvHD usually does not, and 
on the other hand, GvHD can have a partially or totally 
denuded mucosa ( fig. 1 a) which is not a typical MPA ef-
fect, both conditions may, in fact, look identical and can 
thus not be distinguished from each other purely on the 
basis of histology. Taking into account the clinical setting, 
with a history of hematopoietic cell transplantation (in 
rare cases, solid organ transplantation) and a clinical pre-
Table 2.  Histological findings in MPA colonopathy with respect to its differential diagnoses
Condition Histopathological findings  Diagnostic clues
ACE CAD CDC EOS histo pathology history/clinical findings/endoscopy
MPA
colonopathy
++ + ++ + paucicellular (‘empty-appearing’) lamina propria history of TPL and MPA intake, watery 
diarrhea, mostly unremarkable endoscopy
Bowel prepa-
ration effects
+ – – – apoptosis and proliferation in crypt epithelium, may show 
focal active colitis, preserved architecture
mostly unremarkable endoscopy or small 
aphthoid lesions more in distal colon/rectum
GvHD ++ + – – mucosal damage, mucosa might be totally denuded;
possible CAD in late stage
history of bone marrow, stem-cell or (rarely) 
solid organ transplantation; signs of GvHD 
in liver or skin; triad of diarrhea, nausea and 
vomiting; variable endoscopic findings from 
normal-appearing to severely damaged/
denuded mucosa
IBD + ++ – + increase of lamina propria inflammatory cells; active colitis, 
intense neutrophilic activity; chronic and ongoing mucosal 
injury; metaplasia (mucinous or pyloric gland type), 
granulomas; (post-) inflammatory polyps
history of IBD, abdominal pain, fever; 
variable mucous or bloody diarrhea; 
significant mucosal inflammation;
signs of long-standing disease
Acute (self-
limited) infec-
tious colitis
+ – – – focal or diffuse active (neutrophilic) colitis including cryptitis 
and crypt abscesses with a background of preserved crypt 
architecture; variable surface damage and erosions; viral 
cytopathic effects and special stains including immune stains
fever; abdominal pain; mucosa with erythe-
ma, erosions and variable hemorrhage on 
endoscopy
AIDS-related 
(entero-)
colonopathy
++ – – – increased number of apoptoses and decreased number of 
mitotic figures in relation to mucosal injury; changes more 
prominent in small-bowel preserved crypt architecture
known HIV infection; low CD4 cell counts; 
exclusion of infectious agents; mostly 
unremarkable endoscopy
Autoimmune 
enterocolitis
++ + – – villous atrophy; lack of goblet and Paneth (and neuroendo-
crine) cells; lymphocyte-mediated damage of preferentially 
basal parts of crypts (but not surface epithelium); increase of 
lamina propria inflammatory cells
very rare disorder with childhood (onset in 
first year of life) and adult forms; diarrhea 
and weight loss; associated with other 
autoimmune diseases; antienterocyte and 
anti-goblet-cell autoantibodies
Common
variable immu-
nodeficiency
++ – – – decreased count of mucosal plasma cells; GvHD-, IBD-, and 
lymphocytic colitis-like patterns possible in colon; sprue-like 
pattern with villous atrophy and also nodular lymphoid 
hyperplasia and chronic giardiasis in small bowel
gastrointestinal symptoms (diarrhea and 
malabsorption) associated with 
sinopulmonary infections
 – = Not a typical finding; + = a possible finding; ++ = a typical finding; ACE = apoptosis of crypt epithelium; CAD = crypt architectural disarray; CDC = 
cystically dilated crypts; EOS = eosinophils; TPL = transplantation.
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sentation of skin and liver affection, usually gives direc-
tion to the diagnosis of GvHD. However, if patients in the 
right setting for GvHD also have a history of MPA treat-
ment, a distinction based purely on histology might be 
impossible and so has to be made clinically.
 Other conditions with impaired or modulated im-
mune response which have apoptotic colonopathy as a 
histopathological feature are autoimmune enterocolitis, 
common variable immunodeficiency and AIDS-related 
colonopathy ( fig.  1 c, usually observed only in patients 
with very low T cell counts, nowadays rarely observed in 
resource-rich countries due to the implementation of 
combination antiretroviral therapy to decrease HIV rep-
lication and restore immune status). Usually, the clinical 
setting is different and is known, thus rarely implicating 
these conditions as differential diagnoses to MPA effects. 
Moreover, specific or characteristic histopathological 
findings pointing to the underlying disease are a de-
creased count of mucosal plasma cells in common vari-
able immunodeficiency  [14] and a lack of goblet cells or 
Paneth cells in autoimmune enterocolitis  [15] . Drugs, 
other than bowel preparations and MPA, which have 
been reported to lead to increased epithelial apoptosis are 
nonsteroidal anti-inflammatory drugs, anthraquinone 
laxatives  [16] and chemotherapeutic agents, especially 
5-FU  [1, 5] .
 MPA-Induced Colonopathy with Multiple 
Pathologies 
 Patients taking immunosuppressive drugs are at high-
er risk to develop (opportunistic) infections. After hema-
topoietic cell transplantation, patients are at risk for 
GvHD. Therefore, patients on MPA treatment per se who 
develop diarrhea likely have a higher probability of hav-
ing more than one of the above-discussed conditions. We 
have observed several cases in which patients on MPA 
treatment revealed dual or even multiple pathologies. The 
case of a 53-year-old female, who developed diarrhea 
while on MPA treatment for renal transplantation, illus-
trates such a scenario ( fig.  1 d–g). Besides histological 
findings consistent with MPA effects like mild architec-
tural disarray ( fig. 1 d) and an increased number of crypt 
apoptosis, a low-power view showed areas with distinct 
findings already suggesting additional pathologies. A 
high-power view then revealed the presence of tapeworm 
scolices at multiple sites of the mucosa ( fig. 1 d, inset 1) 
which were identified as the dwarf tapeworm  (Hymeno-
lepis nana) . Other areas revealed active colitis with ero-
sions, cystically dilated crypts and multiple EC with both 
nuclear and cytoplasmic inclusions ( fig. 1 d, inset 2) lead-
ing to the diagnosis of CMV infection. In line with our 
observations, in a recently published study on MPA-as-
sociated colitis, Lee et al.  [11] describe dual pathology in 
3 of 7 cases, 2 of which were with concomitant CMV in-
fection. Their findings and our own observations support 
the notion that patients on MPA treatment do indeed 
have a higher risk of developing dual or multiple patholo-
gies. Therefore, when evaluating the colonic biopsies of 
such patients, pathologists must be aware that the histo-
logical picture of MPA effects overlaps with that of other 
conditions. This calls for an active and thorough search 
for additional diagnoses beyond these effects.
 MPA-Induced Colonopathy: Perspectives and 
Unanswered Questions 
 Despite the growing body of literature in recent years 
and the fact that clinicians and pathologists nowadays are 
aware of and familiar with the effects of MPA on the gas-
trointestinal tract, our knowledge is mostly based on ret-
rospective observational and correlative studies, and sev-
eral fundamental questions still remain. These include 
points to be addressed from a basic research as well as a 
clinicopathological perspective. (1) Do the histopatho-
logical findings found in association with MPA treatment 
 [3, 4, 6, 10] correlate with the clinical symptoms, in par-
ticular diarrhea? The current concept is based on this as-
sumption, but there are no data on the frequency of MPA-
typical histopathological changes in patients not suffering 
from diarrhea. (2) What are the dynamics of histopatho-
logical changes and clinical symptoms in relation to MPA 
treatment with respect to occurrence, persistence and re-
versibility? (3) Are there drugs other than MPA which 
can cause the same spectrum of histopathological chang-
es? We have seen, sporadically, colonic biopsies with his-
topathological patterns virtually identical to those of the 
MPA effects in our own practice [unpubl. observation], 
suggesting that these findings probably reflect a stereo-
typical final pathway of several insults rather than an 
MPA-specific pattern. (4) To what extent do MPA effects 
and IBD share pathophysiological mechanisms? The big 
question is: Does long-term treatment with MPA come 
with an increased risk for cancer development going be-
yond the risk attributable to immunosuppression? This is 
conceivable, taking into account our own observation 
that a persistently elevated apoptosis rate may, on its own, 
cause cancer in tissues with the capacity for repair  [17] .
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 Conclusions 
 In recent years, MPA treatment has been identified as 
an underlying cause of apoptotic colonopathy, along with 
the clinical presentation of diarrhea. Characteristic histo-
pathological findings overlap with infectious colitis, IBD 
and GvHD. In daily practice, it is important to recognize 
these features and to consider MPA toxicity, but also to 
not overlook concomitant pathologies like infectious dis-
eases, to which patients on MPA treatment are prone. 
There are important questions relating to the effects of 
MPA on the gastrointestinal tract that remain unan-
swered. It would be pertinent to address the causal rela-
tion and specificity of histopathological findings, the clin-
ical symptoms (in particular, diarrhea) and the question 
of long-term treatment. 
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